BRAINSTORM CELL THERAPEUTICS INC.

For the period ended Dec 31, 2025. Filed Mar 31, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 31, 2026

BCLI$1.14-7.3%Stored close · as of Jul 8, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

ITEM · · Page
· PART I ·
1.	Business	4
1A.	Risk Factors	33
1B.	Unresolved Staff Comments	66
2.	Properties	67
3.	Legal Proceedings	67
4.	Mine Safety Disclosures	68
· PART II ·
5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	69
6.	Reserved	69
7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	69
7A.	Quantitative and Qualitative Disclosures About Market Risk	75
8.	Financial Statements and Supplementary Data	76
9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	106
9A.	Controls and Procedures	106
9B.	Other Information	107
9C.	Disclosure Regarding Foreign Jurisdictions That Prevent Inspections	107
· PART III ·
10.	Directors, Executive Officers and Corporate Governance	108
11.	Executive Compensation	115
12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	122
13.	Certain Relationships and Related Transactions, and Director Independence	123
14.	Principal Accounting Fees and Services	126
· PART IV ·
15.	Exhibits, Financial Statement Schedules	127

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.

About this filing

Table of Contents